NASDAQ: ABIOArca Biopharma Inc Stock
$3.65+0.20 (+5.8%)
Updated Apr 23, 2024
ABIO Price
$3.65
Fair Value Price
$6.44
Market Cap
$52.93M
52 Week Low
$1.56
52 Week High
$3.88
P/E
-9.86x
P/B
1.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$5M
Beta
0.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABIO Overview
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABIO ($3.65) is undervalued by 43.29% relative to our estimate of its Fair Value price of $6.44 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ABIO ($3.65) is significantly undervalued by 43.29% relative to our estimate of its Fair Value price of $6.44 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ABIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABIO due diligence checks available for Premium users.
Be the first to know about important ABIO news, forecast changes, insider trades & much more!
ABIO News
Valuation
ABIO fair value
Fair Value of ABIO stock based on Discounted Cash Flow (DCF)
Price
$3.65
Fair Value
$6.44
Undervalued by
43.29%
ABIO ($3.65) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABIO ($3.65) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.86x
Industry
16.46x
Market
41.92x
ABIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.43x
Industry
5.93x
ABIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.1M
Profit Margin
0%
ABIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$37.9M
Liabilities
$841.0k
Debt to equity
0.02
ABIO's short-term assets ($37.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABIO's short-term assets ($37.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$0.0
ABIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABIO vs Biotech Stocks
Arca Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.